Clearmind Medicine Inc. Logo

Clearmind Medicine Inc.

Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.

CMND | US

Overview

Corporate Details

ISIN(s):
CA1850534027
LEI:
Country:
United States of America
Address:
101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics. The company's primary objective is to commercialize regulated medicines to solve widespread, under-served health problems, with a lead program targeting Alcohol Use Disorder (AUD). Its core treatment candidate is based on the proprietary psychoactive molecule MEAI (5-Methoxy-2-aminoindane), which is currently undergoing Phase I/IIa clinical trials. Clearmind's research is protected by a robust intellectual property portfolio of 19 patent families, underpinning its mission to provide breakthrough treatments for AUD, binge behaviors, and other mental health conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Clearmind Medicine Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Clearmind Medicine Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Clearmind Medicine Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX

Talk to a Data Expert

Have a question? We'll get back to you promptly.